Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | CTRC | Q99895 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7266955 | 0.83 | TDP1 (0.54) | TDP1LMNAALDH1A1HDAC2EGFR | |
| Arundic Acid SCHEMBL5010029 | 0.75 | TDP1 (0.46) | TDP1LMNAALDH1A1HDAC2EGFR | |
| SCHEMBL27559238 | 0.73 | ZDHHC2 (0.46) | TDP1LMNAALDH1A1HDAC2PRSS1 | |
| SCHEMBL9854466 | 0.73 | AKR1C3 (0.50) | ALDH1A1MEN1KMT2AAKR1C3 | |
| SCHEMBL19210261 | 0.72 | LMNA (0.46) | TDP1LMNAALDH1A1EGFRMEN1 | |
| SCHEMBL6518812 | 0.72 | TDP1 (0.55) | TDP1LMNAEGFRMEN1KMT2A | |
| SCHEMBL3675571 | 0.71 | PRSS1 (0.46) | TDP1ALDH1A1HDAC2MEN1KMT2A | |
| SCHEMBL9220321 | 0.71 | TDP1 (0.46) | TDP1LMNAMEN1KMT2AAKR1C3 | |
| SCHEMBL9220318 | 0.71 | TDP1 (0.46) | TDP1LMNAMEN1KMT2AAKR1C3 | |
| SCHEMBL3858716 | 0.70 | GPR84 (0.55) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9249545-A | — | — | None | — | — | JP | disclosed |
| US-20160220479-A1 | TOPICAL COMPOUNDS CONTAINING ADIPOSE-DERIVED HORMONES FOR THE REJUVENATION OF SKIN | OHIO STATE INNOVATION FOUNDATION (US) | 2016-08-04 | — | — | US | disclosed |
| US-9233164-B2 | Water soluble fullerene formulations and methods of use thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2016-01-12 | — | — | US | disclosed |
| WO-2015038951-A1 | TOPICAL COMPOUNDS CONTAINING ADIPOSE-DERIVED HORMONES FOR THE REJUVENATION OF SKIN | OHIO STATE INNOVATION FOUNDATION (US) | 2015-03-19 | — | — | WO | disclosed |
| US-20130323188-A1 | Water Soluble Fullerene Formulations and Methods of Use Thereof | BOARD OF THE REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2013-12-05 | — | — | US | disclosed |
| US-8431550-B2 | Denatured soybean product; topical applying | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| WO-2012097245-A1 | WATER SOLUBLE FULLERENE FORMULATIONS AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2012-07-19 | — | — | WO | disclosed |
| US-8128973-B2 | Medicated skin care preparation for promoting wound healing | MULVANERTY NOREEN (US) | 2012-03-06 | — | — | US | disclosed |
| US-7879823-B2 | Topical application of formulation containing non-denatured, soy product in a carrier for inhibiting the progression of a cutaneous tumor | JOHNSON & JOHNSON CONSUMER COMPANIES (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090136435-A1 | MEDICATED SKIN CARE PREPARATION FOR PROMOTING WOUND HEALING | MULVANERTY NOREEN | 2009-05-28 | — | — | US | disclosed |
| EP-1348441-B1 | Topical anti-cancer compositions | JOHNSON & JOHNSON CONSUMER (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050244523-A1 | Topical anti-cancer compositions and methods of use thereof | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2005-11-03 | — | — | US | disclosed |
| US-20040247713-A1 | Topical anti-cancer compositions and methods of use thereof | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2004-12-09 | — | — | US | disclosed |
| US-20040062731-A1 | Topical anti-cancer compositions and methods of use thereof | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2004-04-01 | — | — | US | disclosed |
| EP-1348441-A1 | Topical anti-cancer compositions | Johnson & Johnson Consumer Companies, Inc. (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20030064049-A1 | Topical anti-cancer compositions and methods of use thereof | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2003-04-03 | — | — | US | disclosed |
| US-6080393-A | COMPRISING RETINOL, RETINAL, RETINYL ACETATE, AND/OR RETINYL PALMITATE IN OIL PHASE WITH GIVEN TOTAL UNSATURATION DENSITY, AND STABILIZER SYSTEM OF ANTIOXIDANTS IN OIL PHASE OR OIL AND WATER PHASES, OR WATER PHASE CHELATING AGENTS; STORAGE STABLE | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. (US) | 2000-06-27 | — | — | US | disclosed |
| JP-H09249545-A | SKIN PREPARATION FOR EXTERNAL USE | SHISEIDO CO LTD | 1997-09-22 | — | — | JP | disclosed |
| WO-1996007396-A9 | RETINOID COMPOSITIONS | — | 1996-09-06 | — | — | WO | disclosed |
| WO-1996007396-A2 | RETINOID COMPOSITIONS | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. (US) | 1996-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130323188-A1 | Water Soluble Fullerene Formulations and Methods of Use Thereof | TP53, SLC46A1, SLC40A1 | TDP1 1859/4885LMNA 1522/4885ALDH1A1 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.